Cite
HARVARD Citation
Song, W. et al. (2018). Targeting newly identified ERβ/TGF‐β1/SMAD3 signals with the FDA‐approved anti‐estrogen Faslodex or an ERβ selective antagonist in renal cell carcinoma. Molecular oncology. 12 (12), pp. 2055-2071. [Online].